On December 8, The Cystic Fibrosis Foundation, in collaboration with the Congressional Cystic Fibrosis Caucus and its co-chairs, U.S. Reps. James McGovern (D-Mass.) and Tom Marino (R-Pa.), presented a congressional briefing on cystic fibrosis and precision medicine.
The U.S. Food and Drug Administration has approved a device, called RELiZORB®, that helps break down beneficial fats in supplemental nutrition provided via G-tubes.
A $7.5 million research award will go to Southern Research to identify potential new drugs for people with rare CF mutations, known as nonsense mutations, Cystic Fibrosis Foundation Therapeutics Inc. announced today.
At the 2015 North American Cystic Fibrosis Conference (NACFC) held on Oct. 8-10 in Phoenix, Arizona, the Cystic Fibrosis Foundation announced the recipients of seven awards given to members of the research and medical community whose achievements have helped advance cystic fibrosis research and care.
The Cystic Fibrosis Foundation and the European Cystic Fibrosis Society have collaborated to create new care guidelines for the
Today, more than 4,000 cystic fibrosis research scientists, clinicians and caregivers are gathering in Phoenix for the 29th Annual North American Cystic Fibrosis Conference (NACFC) in the largest collaborative forum of its kind.
HealthWell to offer co-pay assistance for CF-specific, FDA-approved drugs including prescribed vitamins and supplements.
The House of Representatives has passed a vote on the Ensuring Access to Clinical Trials Act (EACT), which is now set to go to the President for his signature.
Cystic Fibrosis Foundation Vice President of Therapeutics Development Dr. Michael Boyle testified today at a hearing in front of the House Energy and Commerce Committee's Subcommittee on Health. He urged members to support H.R. 209, the Ensuring Access to Clinical Trials Act (EACT), which would make permanent a law enabling people to participate in clinical trials without the fear of losing critical benefits.